GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Other Operating Expense

EyePoint Pharmaceuticals (STU:PV3B) Other Operating Expense : €0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Other Operating Expense?

EyePoint Pharmaceuticals's Other Operating Expense for the three months ended in Dec. 2023 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

EyePoint Pharmaceuticals's quarterly Other Operating Expense increased from Jun. 2023 (€-0.00 Mil) to Sep. 2023 (€0.00 Mil) and increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

EyePoint Pharmaceuticals's annual Other Operating Expense declined from Dec. 2021 (€2.18 Mil) to Dec. 2022 (€1.94 Mil) and declined from Dec. 2022 (€1.94 Mil) to Dec. 2023 (€0.00 Mil).


EyePoint Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for EyePoint Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Other Operating Expense Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.21 2.02 2.18 1.94 -

EyePoint Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 - - - -

EyePoint Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EyePoint Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (STU:PV3B) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines